Deciphera Pharmaceuticals, Inc. (DCPH)
NASDAQ: DCPH · IEX Real-Time Price · USD
14.65
+0.47 (3.31%)
Apr 26, 2024, 4:00 PM EDT - Market closed

Deciphera Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Year Current202320222021202020192018201720162015
Market Capitalization
1,2041,2921,1085713,2493,177791739--
Market Cap Growth
-16.69%93.85%-82.42%2.27%301.89%6.99%---
Enterprise Value
9231,0128123172,7282,615510544-56-24
PE Ratio
-6.63-6.63-6.19-1.90-12.19-16.52-7.92-14.69--
PS Ratio
7.377.918.265.9477.20127.08----
PB Ratio
3.433.683.241.885.985.812.824.02--
P/FCF Ratio
-8.76-8.76-7.21-2.35-13.26-20.60-8.99-19.91--
P/OCF Ratio
-8.81-8.81-7.25-2.37-13.56-21.28-9.11-20.13--
EV/Sales Ratio
5.656.206.063.2964.83104.60----
EV/EBITDA Ratio
-5.39-5.39-4.75-1.08-10.44-13.73-5.13-10.862.171.36
EV/EBIT Ratio
-5.20-5.20-4.56-1.06-10.24-13.61-5.11-10.832.161.36
EV/FCF Ratio
-6.86-6.86-5.28-1.30-11.14-16.96-5.80-14.652.391.78
Debt / Equity Ratio
0.070.070.090.100.060.030.050.01-0.01-0.02
Debt / EBITDA Ratio
-0.14-0.14-0.17-0.11-0.12-0.09-0.13-0.03-0.06-0.11
Debt / FCF Ratio
-0.18-0.18-0.19-0.13-0.13-0.11-0.15-0.04-0.07-0.14
Quick Ratio
3.373.374.013.168.089.6512.9214.2412.618.45
Current Ratio
3.803.804.543.508.349.8813.2414.3512.788.65
Asset Turnover
0.320.320.290.190.060.06000-
Interest Coverage
------2868.49-1187.74-528.31-243.72-7.97
Return on Equity (ROE)
-49.40%-49.40%-51.40%-73.40%-44.30%-47.60%-36.80%-227.50%20.30%-
Return on Assets (ROA)
-38.40%-38.40%-39.30%-58.60%-39.20%-42.70%-33.00%-39.00%-60.50%-
Return on Capital (ROIC)
-55.99%-55.99%-49.28%-89.42%-47.17%-35.58%-35.51%-27.47%18.71%15.52%
Earnings Yield
-16.20%-15.08%-16.16%-52.50%-8.20%-6.05%-12.63%-6.81%--
FCF Yield
-12.25%-11.41%-13.88%-42.49%-7.54%-4.85%-11.12%-5.02%--
Buyback Yield / Dilution
-12.66%-12.66%-29.98%-4.13%-30.12%-21.13%-110.76%-44.43%-173.84%-
Total Shareholder Return
-12.66%-12.66%-29.98%-4.13%-30.12%-21.13%-110.76%-44.43%-173.84%-
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).